Wang Wenjie1, Lu Houqing2, Sun Gengyun3. 1. Department of ICU, Tongling Clinical College of Anhui Medical University, Tongling 244000, Anhui Province, China(1). Electronic address: xbbaax@163.com. 2. Department of ICU, Tongling Clinical College of Anhui Medical University, Tongling 244000, Anhui Province, China(1). Electronic address: 18756208080@163.com. 3. Department of Respiratory Medicine, The First Affiliated Hospital of Medical University of Anhui, Hefei 230022, Anhui Province, China. Electronic address: sungengy@126.com.
Abstract
OBJECTIVE: To evaluate the effect of dexmedetomidine on outcomes following craniocerebral operation and provide evidence for individualized medication. METHODS: We searched the Cochrane Library, PubMed, Springer, CNKI, Wanfang Data Resource and other Chinese and foreign databases with electronic retrieval, within the period 1990-2013, for records relating to dexmedetomidine, brain pharmacokinetics and clinical randomized controlled studies. Records were assessed using the Cochrane system evaluation method for assessing the quality of research, using Revman 5.1 Meta-analysis software. RESULTS: After screening and removal of duplicate documents there were 22 English and 44 Chinese articles, among which there were eight describing clinical trials, with a total of 412 cases. Meta-analysis showed that dexmedetomidine on rate during craniocerebral operation (standardized mean difference=-8.32, 95% confidence interval [CI] -10.38 to 6.26, P<0.00001), and blood pressure (standardized mean difference=-3.37, 95% CI -5.36 to 1.38, P<0.00001). The study had good heterogeneity using random effects model analysis, and there was no publication bias. CONCLUSION: Dexmedetomidine can reduce the hemodynamic response and play a role in brain protection.
OBJECTIVE: To evaluate the effect of dexmedetomidine on outcomes following craniocerebral operation and provide evidence for individualized medication. METHODS: We searched the Cochrane Library, PubMed, Springer, CNKI, Wanfang Data Resource and other Chinese and foreign databases with electronic retrieval, within the period 1990-2013, for records relating to dexmedetomidine, brain pharmacokinetics and clinical randomized controlled studies. Records were assessed using the Cochrane system evaluation method for assessing the quality of research, using Revman 5.1 Meta-analysis software. RESULTS: After screening and removal of duplicate documents there were 22 English and 44 Chinese articles, among which there were eight describing clinical trials, with a total of 412 cases. Meta-analysis showed that dexmedetomidine on rate during craniocerebral operation (standardized mean difference=-8.32, 95% confidence interval [CI] -10.38 to 6.26, P<0.00001), and blood pressure (standardized mean difference=-3.37, 95% CI -5.36 to 1.38, P<0.00001). The study had good heterogeneity using random effects model analysis, and there was no publication bias. CONCLUSION:Dexmedetomidine can reduce the hemodynamic response and play a role in brain protection.